Comparing ACADIA Pharmaceuticals (ACAD) and Its Competitors
ACADIA Pharmaceuticals (NASDAQ: ACAD) is one of 198 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare ACADIA Pharmaceuticals to similar companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, risk, dividends and earnings.
Valuation & Earnings
This table compares ACADIA Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|ACADIA Pharmaceuticals||$62.99 million||-$305.32 million||-13.85|
|ACADIA Pharmaceuticals Competitors||$206.23 million||-$2.30 million||2.07|
ACADIA Pharmaceuticals’ rivals have higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares ACADIA Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ACADIA Pharmaceuticals Competitors||-3,960.95%||-117.55%||-43.31%|
Institutional & Insider Ownership
97.0% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 22.3% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for ACADIA Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ACADIA Pharmaceuticals Competitors||482||2277||6216||120||2.66|
ACADIA Pharmaceuticals presently has a consensus target price of $49.42, indicating a potential upside of 41.03%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.66%. Given ACADIA Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe ACADIA Pharmaceuticals is more favorable than its rivals.
Risk & Volatility
ACADIA Pharmaceuticals has a beta of 3.8, indicating that its share price is 280% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals’ rivals have a beta of 1.63, indicating that their average share price is 63% more volatile than the S&P 500.
ACADIA Pharmaceuticals beats its rivals on 8 of the 12 factors compared.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer’s disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.